Loading...
•
Sep 30, 2020
Mirum Pharmaceuticals Q3 2020 Earnings Report
Mirum Pharmaceuticals reported financial results for the third quarter of 2020 and provided a business update.
Key Takeaways
Mirum Pharmaceuticals reported a net loss of $21.5 million for the quarter ended September 30, 2020. The company's operating expenses were $21.7 million, and it had cash, cash equivalents, and investments of $133.7 million as of September 30, 2020.
Initiated rolling NDA submission for maralixibat in Alagille syndrome.
Launched Expanded Access Program for maralixibat in Alagille syndrome.
Presented five-year transplant-free survival data for patients with PFIC2.
European Marketing Authorization Application submission for maralixibat in PFIC2 planned by year-end 2020.